Skip to main content
Top
Published in: CEN Case Reports 2/2013

01-11-2013 | Case Report

Proliferative glomerulonephritis with monoclonal IgG2κ deposit successfully treated with steroids: a case report and review of the literature

Authors: Ryuji Ohashi, Yukinao Sakai, Tomoyuki Otsuka, Dai Ohno, Yukinari Masuda, Tsuneo Murasawa, Naoki Sato, Akira Shimizu

Published in: CEN Case Reports | Issue 2/2013

Login to get access

Abstract

A novel form of glomerular injury with monoclonal immunoglobulin (Ig) IgG deposition, termed “proliferative glomerulonephritis (GN) with monoclonal IgG deposits” (PGNMID), is a recently described entity. PGNMID presents with various histological patterns, such as membranoproliferative GN, endocapillary proliferative GN and membranous nephropathy (MN). The deposits are composed of monoclonal immunoglobulin, most commonly IgG3 and occasionally IgG2. At present, the clinical significance of each IgG subclass and the morphological patterns of glomerular injury have not been fully investigated due to the limited number of PGNMID cases reported. The patient was a 27-year-old woman presenting with a mild degree of proteinuria and no other physical or serological abnormalities. Monoclonal Ig could not be identified in her serum or urine. Renal biopsy found features of MN with deposition of monoclonal IgG2κ. Electron microscopy examination revealed non-organised electron-dense deposits predominantly in subepithelial locations. Based on a diagnosis of PGNMID, she was treated with prednisolone and proteinuria significantly decreased in less than 4 weeks. Although the clinical outcomes of PGNMID remain to be defined, MN features may possibly be a sign of favourable prognosis—a hypothesis supported by recent reports. The absence of advanced chronic damage in the kidney, such as glomerulosclerosis or tubulointerstitial fibrosis, may also have contributed to the favourable outcome in the present case. Further studies on additional PGNMID cases that allow the correlation of morphological features and IgG subclasses with clinical outcomes are needed in order to confirm our findings and further solidify the clinical aspects of this new disease entity.
Literature
1.
go back to reference Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.PubMedCrossRef Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.PubMedCrossRef
3.
go back to reference Kiremitci S, Calayoglu R, Ensari A, Erbay B. Pathologist’s puzzle: membranoproliferative glomerulonephritis-like features in cryoglobulinemic glomerulonephritis. Pathol Res Pract. 2012;208:254–8.PubMedCrossRef Kiremitci S, Calayoglu R, Ensari A, Erbay B. Pathologist’s puzzle: membranoproliferative glomerulonephritis-like features in cryoglobulinemic glomerulonephritis. Pathol Res Pract. 2012;208:254–8.PubMedCrossRef
4.
go back to reference D’Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. 1995;25:361–9.PubMedCrossRef D’Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. 1995;25:361–9.PubMedCrossRef
5.
go back to reference Korbet SM, Schwartz MM, Lewis EJ. Immuotactoid glomerulopathy (fibrillary glomerulonephritis). Clin J Am Soc Nephrol. 2006;1:1351–6.PubMedCrossRef Korbet SM, Schwartz MM, Lewis EJ. Immuotactoid glomerulopathy (fibrillary glomerulonephritis). Clin J Am Soc Nephrol. 2006;1:1351–6.PubMedCrossRef
6.
go back to reference Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008;19:34–7.PubMedCrossRef Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008;19:34–7.PubMedCrossRef
7.
go back to reference Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef
8.
go back to reference Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231–9.PubMedCrossRef Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231–9.PubMedCrossRef
9.
go back to reference Komatsuda A, Masai R, Ohtani H, Togashi M, Maki N, Sawada K, et al. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant. 2008;23:3888–94.PubMedCrossRef Komatsuda A, Masai R, Ohtani H, Togashi M, Maki N, Sawada K, et al. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant. 2008;23:3888–94.PubMedCrossRef
10.
go back to reference Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6:1609–16.PubMedCrossRef Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6:1609–16.PubMedCrossRef
11.
go back to reference Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant. 2011;26:2712–4.PubMedCrossRef Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant. 2011;26:2712–4.PubMedCrossRef
12.
go back to reference Fujita E, Shimizu A, Kaneko T, Masuda Y, Ishihara C, Mii A, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G3κ deposits in association with parvovirus B19 infection. Hum Pathol. 2012;43:2326–33.PubMedCrossRef Fujita E, Shimizu A, Kaneko T, Masuda Y, Ishihara C, Mii A, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G3κ deposits in association with parvovirus B19 infection. Hum Pathol. 2012;43:2326–33.PubMedCrossRef
13.
go back to reference Yamada T, Arakawa Y, Mii A, Kashiwagi T, Kaneko T, Utsumi K, et al. A case of monoclonal immunoglobulin G1-lambda deposition associated with membranous feature in a patient with hepatitis C viral infection. Clin Exp Nephrol. 2012;16:468–72.PubMedCrossRef Yamada T, Arakawa Y, Mii A, Kashiwagi T, Kaneko T, Utsumi K, et al. A case of monoclonal immunoglobulin G1-lambda deposition associated with membranous feature in a patient with hepatitis C viral infection. Clin Exp Nephrol. 2012;16:468–72.PubMedCrossRef
14.
go back to reference Grey HM, Kunkel HG. H chain subgroups of myeloma proteins and normal 7s gamma-globulin. J Exp Med. 1964;120:253–66.PubMedCrossRef Grey HM, Kunkel HG. H chain subgroups of myeloma proteins and normal 7s gamma-globulin. J Exp Med. 1964;120:253–66.PubMedCrossRef
15.
go back to reference Terry WD, Fahey JL. Subclasses of human gamma-2-globulin based on differences in the heavy polypeptide chains. Science. 1964;146:400–1.PubMedCrossRef Terry WD, Fahey JL. Subclasses of human gamma-2-globulin based on differences in the heavy polypeptide chains. Science. 1964;146:400–1.PubMedCrossRef
16.
go back to reference Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661–7.PubMedCrossRef Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661–7.PubMedCrossRef
17.
go back to reference Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4:89–99.PubMedCrossRef Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4:89–99.PubMedCrossRef
18.
go back to reference Capra JD, Kunkel HG. Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome. J Clin Invest. 1970;49:610–21.PubMedCrossRef Capra JD, Kunkel HG. Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome. J Clin Invest. 1970;49:610–21.PubMedCrossRef
19.
go back to reference Masai R, Wakui H, Komatsuda A, Togashi M, Maki N, Ohtani H, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009;72:46–54.PubMedCrossRef Masai R, Wakui H, Komatsuda A, Togashi M, Maki N, Ohtani H, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009;72:46–54.PubMedCrossRef
Metadata
Title
Proliferative glomerulonephritis with monoclonal IgG2κ deposit successfully treated with steroids: a case report and review of the literature
Authors
Ryuji Ohashi
Yukinao Sakai
Tomoyuki Otsuka
Dai Ohno
Yukinari Masuda
Tsuneo Murasawa
Naoki Sato
Akira Shimizu
Publication date
01-11-2013
Publisher
Springer Japan
Published in
CEN Case Reports / Issue 2/2013
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-013-0064-3

Other articles of this Issue 2/2013

CEN Case Reports 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.